Physician profile
James Mitchell Lipstate
NPI 1043260607
$13,909.95
in general payments reported to CMS, 2019-2025
58 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,392 · 2020: $1,524 · 2021: $3,654 · 2022: $1,753 · 2023: $2,103 · 2024: $2,240 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,567 · Education: $19.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,567.22 |
| Education | $19.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,324.59 | 2019-2024 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $1,997.01 | 2019-2024 | |
| Tandem Diabetes Care, INC. | $1,700.00 | 2021 | |
| Glaxosmithkline, LLC. | $819.97 | 2019-2025 | Benlysta |
| Ucb, INC. | $799.08 | 2019-2024 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $679.68 | 2019-2024 | |
| Aurinia Pharma U.S., INC. | $641.90 | 2021-2024 | Lupkynis |
| Genentech USA, INC. | $413.62 | 2019-2023 | Actemra |
| Janssen Biotech, INC. | $395.96 | 2020-2024 | Tremfya |
| Pfizer INC. | $377.21 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $355.04 | 2021-2024 | Saphnelo |
| Radius Health, INC. | $344.89 | 2019-2024 | Tymlos |
| Corcept Therapeutics | $232.00 | 2021-2024 | Korlym |
| Genzyme Corporation | $228.82 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.32 | 2020-2023 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $196.35 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $176.89 | 2019-2022 | |
| Novo Nordisk INC | $133.99 | 2021-2024 | Ozempic |
| Antares Pharma, INC. | $117.87 | 2019-2021 | |
| Medexus Pharma, INC. | $113.00 | 2019 | |
| Fresenius Kabi USA, LLC | $108.93 | 2023-2024 | Idacio |
| Merck Sharp & Dohme LLC | $105.36 | 2021-2023 | Steglatro, Steglujan, Segluromet |
| Insulet Corporation | $102.30 | 2024 | Omnipod |
| Beta Bionics, INC. | $99.13 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Abbott Laboratories | $95.54 | 2019 | |
| Celgene Corporation | $94.56 | 2019 | |
| Mallinckrodt Hospital Products INC. | $93.71 | 2021-2024 | Acthar |
| Sobi, INC | $92.93 | 2022-2024 | |
| Ani Pharmaceuticals, INC. | $81.77 | 2022-2024 | Purified Cortrophin Gel |
| Recordati_rare_diseases_inc. | $78.60 | 2020-2024 | Signifor Lar, Isturisa |
| Xeris Pharmaceuticals, INC. | $74.34 | 2023 | Recorlev |
| E.R. Squibb & Sons, L.L.C. | $68.64 | 2024 | Orencia |
| Amarin Pharma, INC. | $59.45 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $54.42 | 2019-2020 | |
| Becton, Dickinson and Company | $36.40 | 2021-2022 | |
| Shire North American Group INC | $32.02 | 2019 | |
| Medtronic, INC. | $25.66 | 2023 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Amryt Pharma Holdings LTD | $25.24 | 2023 | Mycapssa |
| Ibsa Pharma INC. | $24.00 | 2022 | |
| Chiesi USA, INC. | $22.49 | 2024 | Mycapssa |
| Teva Pharmaceuticals USA, INC. | $22.44 | 2024 | Truxima |
| Kiniksa Pharmaceuticals International, Plc | $21.60 | 2024 | Arcalyst |
| Depuy Synthes Sales INC. | $21.08 | 2021 | |
| Celltrion USA INC. | $19.97 | 2023 | Yuflyma |
| Sequel Med Tech, LLC | $18.84 | 2025 | Twiist |
| Sanofi-Aventis U.S. LLC | $18.10 | 2024 | |
| Ascendis Pharma Endocrinology INC | $17.39 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $15.84 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.87 | 2022 | |
| Mallinckrodt Enterprises LLC | $14.85 | 2019 | |
| Sandoz INC. | $14.58 | 2025 | |
| Alexion Pharmaceuticals, INC. | $14.41 | 2023 | Strensiq |
| Janssen Pharmaceuticals, INC | $14.08 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $13.04 | 2022 | |
| Cequr Corporation | $12.75 | 2024 | Cequr Simplicity |
| Clarus Therapeutics INC. | $11.35 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.06 | 2021 | |
| Vivus LLC | $8.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lipstate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.